In our last podcast, we touched on topics around:

1. policy breakthroughs and current regulatory barriers in pilot zones across China,

2. applying real-world data to streamline the review of imported medical products,

3. the lingering challenges for patients to access innovative healthcare products that have already launched overseas

4. some suggestions for future policy breakthroughs.

In this podcast, we cover why imported innovative medical devices account for only 15% of green channel approvals in China—and what needs to change.

We also break down:
✅ Why 60% of top hospitals delay adoption by 6–12 months
✅ How NRDL timelines shrank from 5 years to 1, yet access remains limited
✅ The policy fixes needed—from RWE mandates to national innovation definitions

Tune in for the full discussion.

In this podcast, we will mostly dive into some of the latest but also long-standing industry and regulatory issues in China surrounding the accessibility of innovative healthcare products, their current policy regulation standings, and what are areas where the industry can call for additional improvement actions.

These actions will not only benefit multinational and domestic healthcare businesses, but also will improve China’s overall healthcare landscape and development quality.